Orlent H - Search Results

1

Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial.

Orlent H, Hansen BE, Willems M, Brouwer JT, Huber R, Kullak-Ublick GA, Gerken G, Zeuzem S, Nevens F, Tielemans WC, Zondervan PE, Lagging M, Westin J, Schalm SW. Orlent H, et al. J Hepatol. 2006 Oct;45(4):539-46. doi: 10.1016/j.jhep.2006.05.015. Epub 2006 Jun 30. J Hepatol. 2006. PMID: 16905220 Clinical Trial.

2

[The treatment of hepatitis C].

Orlent H, Vrolijk JM, de Man RA, Schalm SW. Orlent H, et al. Ned Tijdschr Geneeskd. 2003 Jun 21;147(25):1208-13. Ned Tijdschr Geneeskd. 2003. PMID: 12848055 Review. Dutch.

3

Hepatitis C 2002 guidelines: summary and annotations.

Orlent H, Vrolijk JM, Veldt BJ, Schalm SW. Orlent H, et al. Scand J Gastroenterol Suppl. 2003;(239):105-10. doi: 10.1080/00855920310002780. Scand J Gastroenterol Suppl. 2003. PMID: 14743892 Review.

4

The treatment of hepatitis C: history, presence and future.

Vrolijk JM, de Knegt RJ, Veldt BJ, Orlent H, Schalm SW. Vrolijk JM, et al. Among authors: orlent h. Neth J Med. 2004 Mar;62(3):76-82. Neth J Med. 2004. PMID: 15209471 Free article. Review.

5

Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1.

Orlent H, Mathot RA, Van Bommel EF, Vulto AG, Schalm SW, Brouwer JT. Orlent H, et al. Dig Dis Sci. 2005 Oct;50(10):1804-6. doi: 10.1007/s10620-005-2941-x. Dig Dis Sci. 2005. PMID: 16187177 No abstract available.

6

Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B.

Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H. Verhelst X, et al. Among authors: orlent h. Eur J Gastroenterol Hepatol. 2010 Apr;22(4):494-9. doi: 10.1097/meg.0b013e3283329d13. Eur J Gastroenterol Hepatol. 2010. PMID: 20306568 Review.

7

Progressive multifocal leukoencephalopathy in liver transplant recipients: a case report and review of the literature.

Verhelst X, Vanhooren G, Vanopdenbosch L, Casselman J, Laleman W, Pirenne J, Nevens F, Orlent H. Verhelst X, et al. Among authors: orlent h. Transpl Int. 2011 Apr;24(4):e30-4. doi: 10.1111/j.1432-2277.2010.01190.x. Epub 2010 Dec 7. Transpl Int. 2011. PMID: 21134241 Free article. Review.

8

Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.

Orlent H, Desombere I, Hansen B, Van Vlierberghe H, Haagmans B, De Knegt RJ, Schalm SW, Leroux-Roels G, Janssen HL; DITTO-HCV Study Group. Orlent H, et al. Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1443-8. doi: 10.1097/MEG.0b013e32833ef6e3. Eur J Gastroenterol Hepatol. 2010. PMID: 21389795 Clinical Trial.

9

High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C.

Orlent H, Hansen B, Janssen HL, De Knegt RJ. Orlent H, et al. Dig Liver Dis. 2015 Jan;47(1):87-8. doi: 10.1016/j.dld.2014.09.011. Epub 2014 Oct 11. Dig Liver Dis. 2015. PMID: 25308611 No abstract available.

10

Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study.

Vandenbulcke H, Moreno C, Colle I, Knebel JF, Francque S, Sersté T, George C, de Galocsy C, Laleman W, Delwaide J, Orlent H, Lasser L, Trépo E, Van Vlierberghe H, Michielsen P, van Gossum M, de Vos M, Marot A, Doerig C, Henrion J, Deltenre P. Vandenbulcke H, et al. Among authors: orlent h. J Hepatol. 2016 Sep;65(3):543-51. doi: 10.1016/j.jhep.2016.04.031. Epub 2016 May 13. J Hepatol. 2016. PMID: 27180899 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters